Brief: InMed Pharmaceuticals Announces Commencement Of Phase 2 Clinical Trial Investigating Cannabinol In The Treatment Of Epidermolysis Bullosa
30/09/2021 12:38
Sept 30 (Reuters) - InMed Pharmaceuticals Inc INM.O :
* INMED PHARMACEUTICALS ANNOUNCES COMMENCEMENT OF PHASE 2
CLINICAL
TRIAL INVESTIGATING CANNABINOL (CBN), A RARE CANNABINOID, IN THE
TREATMENT OF EPIDERMOLYSIS BULLOSA
* INMED - STUDY WILL BE TAKING PLACE AT ELEVEN SITES ACROSS
SEVEN
COUNTRIES INCLUDING AUSTRIA, GERMANY, GREECE, FRANCE, ITALY,
ISRAEL AND SERBIA
Source text for Eikon: ID:nGNX5TXy5j
Further company coverage: INM.O
((Reuters.Briefs@thomsonreuters.com;))